Orient Pharma (4166) reported revenue of NT$148 million for Oct 2026, -1.3% year on year and -0.5% from the previous month. Revenue for Jan–Oct 2026 was NT$1.3 billion (+17.5% year on year).
In Oct 2026, it ranked No. 56 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$148 million | -1.3% | -0.5% |
| Sep 2026 | NT$148.8 million | +41.2% | +28.4% |
| Aug 2026 | NT$115.9 million | +14.9% | -12.1% |
| Jul 2026 | NT$131.8 million | +20.1% | -28.0% |
| Jun 2026 | NT$183 million | +68.3% | +61.9% |
| May 2026 | NT$113 million | -0.9% | -13.8% |
| Apr 2026 | NT$131 million | +27.6% | +21.8% |
| Mar 2026 | NT$107.6 million | +14.8% | +37.6% |
| Feb 2026 | NT$78.2 million | -14.6% | -46.2% |
| Jan 2026 | NT$145.4 million | +10.5% | +10.4% |
| Dec 2025 | NT$131.7 million | +19.4% | -17.7% |
| Nov 2025 | NT$160 million | +47.2% | +6.7% |
| Oct 2025 | NT$150 million | +65.7% | +42.3% |
| Sep 2025 | NT$105.4 million | +5.0% | +4.5% |
| Aug 2025 | NT$100.9 million | +0.1% | -8.1% |
| Jul 2025 | NT$109.8 million | +8.2% | +0.9% |
| Jun 2025 | NT$108.8 million | +7.6% | -4.6% |
| May 2025 | NT$114 million | +10.8% | +11.0% |
| Apr 2025 | NT$102.7 million | -15.1% | +9.5% |
| Mar 2025 | NT$93.8 million | -5.3% | +2.4% |
| Feb 2025 | NT$91.6 million | +17.3% | -30.4% |
| Jan 2025 | NT$131.5 million | +33.0% | +19.2% |
| Dec 2024 | NT$110.3 million | +21.7% | +1.5% |
| Nov 2024 | NT$108.7 million | +52.0% | +20.0% |
| Oct 2024 | NT$90.6 million | +10.3% | -9.8% |
Jan–Oct 2026 cumulative: NT$1.3 billion (+17.5% YoY)
Other Biotech & Medical companies
Compare with peers: Orient Pharma vs PEC / Orient Pharma vs Lotus Pharm / Orient Pharma vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16